# Oral administration of curcumin and quercetin nanoparticles can improve ulcerative colitis by regulating intestinal microorganisms

**Authors:** Yingxi Li, Zhiyue Xu, Shiyang Zhao, Tianyi Huang, Jianzhong Xu, Sitong Wang, Yaxin Sang, Wenlong Yu, Xianghong Wang

PMC · DOI: 10.3389/fnut.2025.1696699 · 2025-10-01

## TL;DR

Nanoparticles containing curcumin and quercetin can reduce inflammation and improve ulcerative colitis by regulating gut bacteria and enhancing drug delivery to the colon.

## Contribution

A novel nanoparticle formulation (Zein-CS-Cur-Que) is developed to improve curcumin targeting and efficacy in treating ulcerative colitis.

## Key findings

- Zein-CS-Cur-Que reduces pro-inflammatory factors and increases anti-inflammatory IL-10 in UC mice.
- The nanoparticles restore intestinal barrier function by up-regulating tight junction proteins like ZO-1 and Claudin-1.
- They modulate gut microbiota and increase short-chain fatty acids, reversing UC-related damage.

## Abstract

Curcumin has been proved to relieve ulcerative colitis (UC). However, the premature release of gastrointestinal tract will lead to insufficient accumulation of curcumin in colon and affect the improvement effect. Therefore, we developed a kind of oral nanoparticles (Zein-CS-Cur-Que), which made quercetin promote the absorption of curcumin in colon by efflux carrier and inhibiting metabolic enzymes, and at the same time encapsulated curcumin and quercetin with zein and sodium caseinate to promote the targeted release in colon.

3.5% dextran sodium sulfate was used to establish ulcerative colitis (UC) model in mice, and the improvement effect of nanoparticles on ulcerative colitis was evaluated by comprehensive basic score (weight change rate, DAI score, liver index, and spleen index), inflammatory factors (TNF-α, IL-1β, IL-6, IL-10, and IFN-γ) and oxidative stress (MDA, SOD, CAT, and MPO). The intestinal flora was sequenced by 16S rRNA, and the secretion of short-chain fatty acids was determined by GC-MS. Immunohistochemistry (ZO-1, Claudin-1, and Occludin) and real-time quantitative reverse transcription PCR (qRT-PCR) (TLR4/NF-κB and JAK2/STAT3) were used to analyze the expression of related genes.

The results showed that Zein-CS-Cur-Que can reduce pro-inflammatory factors (INF-γ, IL-6, IL-1β, and TNF-α), increase anti-inflammatory factor (IL-10), up-regulate the expression level of tight junction proteins (ZO-1, Claudin-1, and Occludin) to restore the intestinal barrier, and down-regulate the expression of related protein genes in TLR4/NF-κB and JAK2/STAT3. Ultimately, modulating the relative abundance of Firmicutes and Bacteroidetes promotes the production of short-chain fatty acids and reverses the damage caused by ulcerative colitis.

Nanoparticles (Zein-CS-Cur-Que) can significantly reduce inflammatory reaction, restore intestinal barrier, regulate the expression of related protein genes in TLR4/NF-κB and JAK2/STAT3 pathways, and significantly improve ulcerative colitis. Furthermore, the construction of Zein-CS-Cur-Que provides a scientific basis for increasing curcumin targeting and ameliorating ulcerative colitis.

## Linked entities

- **Genes:** TNF (tumor necrosis factor) [NCBI Gene 7124], IL1B (interleukin 1 beta) [NCBI Gene 3553], IL6 (interleukin 6) [NCBI Gene 3569], IL10 (interleukin 10) [NCBI Gene 3586], IFNG (interferon gamma) [NCBI Gene 3458], TJP1 (tight junction protein 1) [NCBI Gene 7082], CLDN7 (claudin 7) [NCBI Gene 1366], si:ch73-61d6.3 (uncharacterized si:ch73-61d6.3) [NCBI Gene 103182021], TLR4 (toll like receptor 4) [NCBI Gene 7099], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790], JAK2 (Janus kinase 2) [NCBI Gene 3717], STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774]
- **Chemicals:** curcumin (PubChem CID 969516), quercetin (PubChem CID 5280343), MDA (PubChem CID 1614), MPO (PubChem CID 3270828)
- **Diseases:** ulcerative colitis (MONDO:0005101)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Cat (catalase) [NCBI Gene 12359] {aka 2210418N07, Cas-1, Cas1, Cs-1}, Ifng (interferon gamma) [NCBI Gene 15978] {aka IFN-g, If2f, Ifg}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, Stat3 (signal transducer and activator of transcription 3) [NCBI Gene 20848] {aka 1110034C02Rik, Aprf}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Mpo (myeloperoxidase) [NCBI Gene 17523] {aka mKIAA4033}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Il10 (interleukin 10) [NCBI Gene 16153] {aka CSIF, If2a, Il-10}, Ocln (occludin) [NCBI Gene 18260] {aka Ocl}, Cldn1 (claudin 1) [NCBI Gene 12737], Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Jak2 (Janus kinase 2) [NCBI Gene 16452] {aka Fd17}, Tjp1 (tight junction protein 1) [NCBI Gene 21872] {aka ZO1}
- **Diseases:** UC (MESH:D003093), inflammatory (MESH:D007249)
- **Chemicals:** Curcumin (MESH:D003474), short-chain fatty acids (MESH:D005232), CS (MESH:D002586), quercetin (MESH:D011794), Cur (-), MDA (MESH:D015104)
- **Species:** Bacteroidia (class) [taxon 200643], Bacillota (clostridial firmicutes, phylum) [taxon 1239], Mus musculus (house mouse, species) [taxon 10090]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12523446/full.md

---
Source: https://tomesphere.com/paper/PMC12523446